Reference

1. National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. Monoclonal Antibody Production. Washington (DC): National Academies Press (US); 1999. COMMITTEE ON METHODS OF PRODUCINGMONOCLONAL ANTIBODIES. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100201/
2. Kumagai Izumi and Tsumoto Kouhei (Published- 19 April 2010) ‘Antigen-Antibody Binding’ Introduction pg-1, Wiley Online Library, Available from: https://doi.org/10.1002/9780470015902.a0001117.pub2
3. Ratheesh Krishna Kripa, ’Antigen and Antibody Reaction’ June 30, 2019 SlideShare, Definition of Antigen-2. Available from:  https://www.slideshare.net/Ratheeshrikrishnakripa/antigen-antibody-reaction-152721326
4. Ehrlich Paul 1900 Croonian lecture. On immunity with special reference to cell life Proc. R. Soc. Lond.66:424–448 Available from: http://doi.org/10.1098/rspl.1899.0121
5. Nelson, A., Dhimolea, E. Reichert, J. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9, 767–774 (2010). Available from:  https://doi.org/10.1038/nrd3229
6. Maggon K. ‘Monoclonal antibody’ "gold rush". Curr Med Chem. 2007;14(18):1978-87. Doi: 10.2174/092986707781368504. PMID: 17691940. Available from: https://pubmed.ncbi.nlm.nih.gov/17691940/
7. Li, J., Zhu, Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 31, 1198–1207 (2010). Available from: https://doi.org/10.1038/aps.2010.120
8. KÖHLER, G., MILSTEIN, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975). Available from: https://doi.org/10.1038/256495a0
9. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002 Jul;324(1):14-30. Doi: 10.1097/00000441-200207000-00004. PMID: 12120821; PMCID: PMC7093874.
10. Milstein C. With the benefit of hindsight. Immunol Today. 2000 Aug;21(8):359-64. Doi: 10.1016/s0167-5699(00)01660-1. PMID: 10916137.
11. Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today. 2000 Aug;21(8):364-70. Doi: 10.1016/s0167-5699(00)01668-6. PMID: 10916138.
12. Li F, Vijaya Sankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. MAbs. 2010 Sep-Oct;2(5):466-79. Doi: 10.4161/mabs.2.5.12720. Epub 2010 Sep 1. PMID: 20622510; PMCID: PMC2958569.
13. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021 Oct 18;19(1):159. Doi: 10.1186/s43141-021-00264-6. PMID: 34661773; PMCID: PMC8521504.
14. Clementi N, Mancini N, Solforosi L, Castelli M, Clementi M, Burioni R. Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int J Mol Sci. 2012;13(7):8273-8292. Doi: 10.3390/ijms13078273. Epub 2012 Jul 4. PMID: 22942702; PMCID: PMC3430233.
15. Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple SDj, Clarke KF, et.al. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 2007;8(11): R254. Doi: 10.1186/gb-2007-8-11-r254. PMID: 18047641; PMCID: PMC2258204.
16. Schirrmann T, Meyer T, Schütte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules. 2011 Jan 10;16(1):412-26. Doi: 10.3390/molecules16010412. PMID: 21221060; PMCID: PMC6259421.
17. Watkins NA, Ouwehand WH. Introduction to antibody engineering and phage display. Vox Sang. 2000;78(2):72-9. Doi: 10.1159/000031154. PMID: 10765141.
18. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today. 2000 Aug;21(8):371-8. Doi: 10.1016/s0167-5699(00)01667-4. PMID: 10916139.
19. Chistensen D J, Gottlin E B, Benson R E. (2001). “Phage display for target-based antibacterial drug discovery”. Drug Discovery Today 6(14):721-727.  Available from: https://www.creative-biolabs.com/drug-discovery/therapeutics/hts-based-on-phage-display.htm
20. Sophie LE RAY, ProteoGenix, ‘Hybridoma vs Phage Display Technology’ Industry Insights published- Jan 30,2019. Available from:https://www.technologynetworks.com/drug-discovery/blog/hybridoma-vs-phage-display-for-monoclonal-antibody-production-which-technique-for-which-purpose-314741
21. Schur PH. IgG subclasses--a review. Annals of Allergy. 1987 Feb;58(2):89-96, 99. PMID: 3544971.
22. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol. 1974;19(0):259-94. Doi: 10.1016/s0065-2776(08)60254-0. PMID: 4611173.
23. C Molnar.2015 ‘23.3. Antibodies -Concepts of Biology’ BCcampus open publishing. Available from: https://opentextbc.ca/biology/chapter/23-3-antibodies/
24. US-FDA Guidance Document- Points to consider in manufacture and testing of Monoclonal Antibody Production for human use, February 1997, Docket number- FDA-1994-D-0318, Issued by- Centre for Biologics Evaluation and Research, Centre for Drug Evaluation and Research, USFDA. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-manufacture-and-testing-monoclonal-antibody-products-human-use
25. US-FDA Guidance Document- S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, November 1997, Docket number- FDA-1997-D-0265, Issued by- Centre for Biologics Evaluation and Research, Centre for Drug Evaluation and Research, USFDA. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals
26. Omudhome Ogbru and Charles Patrick, ‘Monoclonal Antibodies’, Medicine Net, medically reviewed-10/12/2022. Available from:https://www.medicinenet.com/monoclonal_antibodies/drug-class.htm
27. Sandhya P., Nicholas D.,Nandan S.,Aminda S.,Jamie N.,Misbah B. et.al, ‘ Monoclonal Antibody drugs for cancer: How they Work’. Available from:  https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-200047808
28. Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic     

monoclonal antibodies: what cardiologists need to know. Circulation. 2013 Jun 4;127(22):2222-30. Doi: 10.1161/CIRCULATIONAHA.113.002033. PMID: 23733968.

29. Guimaraes Koch SS, Thorpe R, Kawasaki N, Lefranc MP, Malan S, Martin ACR, et.al. International non-proprietary names for monoclonal antibodies: an evolving nomenclature system. MAbs. 2022 Jan-Dec;14(1):2075078. Doi: 10.1080/19420862.2022.2075078. PMID: 35584276; PMCID: PMC9122354.

30. Cancer available from – https://www.cancer.gov/about- cancer/understanding/what-is-cancer

31. Bethesda (MD)- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Antineoplastic Agents. [Updated 2023 Feb 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548022/

32. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002 Nov;13 Suppl 2: S3-10. Doi: 10.1097/00001813-200211002-00002. PMID: 12710585.
33. Faith S., Yuette Brazier and Tom Rush, ‘What are the different types of tumours?’, by- Medical News Today, Updated on- February 10, 2023. Available from: https://www.medicalnewstoday.com/articles/249141
34.  Available From– https://medlineplus.gov/ency/article/000816.htm
35. Puthenpurail A, Rathi H, Nauli SM, Ally A. A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. World J Pharm Sci. 2021 Nov;10(11):14-22. PMID: 35071113; PMCID: PMC8775886.
36. Rituximab- 20 September 2020. Available from: https://nras.org.uk/resource/b-cell-inhibitor-rituximab/?print-pdf=3455
37. Asthma: Types, Causes, Symptoms, Diagnosis and Treatment – 19 Jan 2022. Available from: https://my.clevelandclinic.org/health/diseases/6424-asthma
38. Kumar C, Zito PM. Omalizumab. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545183/
39. Omalizumab Mechanism of Action Available From – https://www.uptodate.com/contents/image?imageKey=ALLRG/59320
40. Darragh O’ Carroll and S.Srakocic, ‘Monoclonal Antibody Treatment for COVID-19’- Healthline Media September 21,2022. Available from: https://www.healthline.com/health/what-is-monoclonal-antibody-treatment
41. Kauvery hospital- July 16,2021,”Monoclonal antibody treatment used for COVID-19”. Available from: https://kauveryhospital.com/blog/vaccination/monoclonal-antibodies-and-covid-19-treatment/
42. Nandkishhor Jha, “Applications of monoclonal antibodies : 4 applications”. Available from – https://www.biologydiscussion.com/biotechnology/applications-of- monoclonal-antibodies-4-applications/10045
43. Himal Barakoti,‘Monoclonal Antibodies: Preparation, Evaluation and Application’, SlideShare-9,10 – February 06,2019. Available from: https://www.slideshare.net/HimalBarakoti/monoclonal-antibodies-130716465
44. Sepmag, ‘Protein Purification: the step-by-step process’ – April 28,2022. Available from: https://www.sepmag.eu/blog/bid/371789/the-step-by-step-process-of-protein-purification